Payment overview · 2025
General Payments
$1,403.08
79 reported records · 27 companies
Healthcare provider profile · identity verified
Sierra Nash
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CORYDON, IN · NPI 1902455256
Verified facts
What the public records show
CMS Open Payments records show Sierra Nash received $1,403.08 in general payments during 2025 across 79 reported records.
ABBVIE INC. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $221.90 | 15.8% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.11 | 13.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.50 | 12.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $151.82 | 10.8% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.07 | 4.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.70 | 4.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $50.11 | 3.6% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $49.98 | 3.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$43.23 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.01 | 2.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $37.00 | 2.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.60 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.93 | 2.4% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $25.35 | 1.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.31 | 1.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $23.97 | 1.7% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.09 | 1.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $20.99 | 1.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.85 | 1.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $20.12 | 1.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.04 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.72 | 1.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.18 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.43 | 1.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.85 | 1.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.82 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,403.08 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $167.25 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.72 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $108.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.16 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.16 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.80 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.12 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $61.13 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.07 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.70 | 3 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $49.98 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $48.52 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $48.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $45.78 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $37.95 | 3 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.60 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $32.33 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $25.35 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $12.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 248 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 54 |
| Gabapentin | Gabapentin | 153 | 48 |
| Lisinopril | Lisinopril | 142 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 41 |
| Montelukast Sodium | Montelukast Sodium | 133 | 40 |
| Losartan Potassium | Losartan Potassium | 129 | 42 |
| Omeprazole | Omeprazole | 122 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 29 |
| Potassium Chloride | Potassium Chloride | 95 | 28 |
| Tramadol Hcl | Tramadol Hcl | 92 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 22 |
| Alprazolam | Alprazolam | 75 | 17 |
| Simvastatin | Simvastatin | 74 | 27 |
| Atenolol | Atenolol | 66 | 22 |
| Clonazepam | Clonazepam | 65 | 15 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 16 |
| Metformin Hcl | Metformin Hcl | 62 | 26 |
| Pregabalin | Pregabalin | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 12 |
| Celecoxib | Celecoxib | 59 | 21 |
| Furosemide | Furosemide | 56 | 23 |
| Meloxicam | Meloxicam | 56 | 22 |
| Ozempic | Semaglutide | 54 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 14 |
| Glipizide Er | Glipizide | 42 | 17 |
| Ondansetron Odt | Ondansetron | 40 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 11 |
| Trazodone Hcl | Trazodone Hcl | 34 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 25 | 11 |
| Prednisone | Prednisone | 25 | 21 |
| Famotidine | Famotidine | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Baclofen | Baclofen | 22 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,403.08 · 79 records | ABBVIE INC. | AIRSUPRA, Andembry, Auvelity, Azstarys, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, DUPIXENT, Dyanavel XR, ENTYVIO, FARXIGA, IBSRELA, INJECTAFER, JOURNAVX, LINZESS, MAVYRET, MINIMED 780G, NURTEC ODT, OMVOH, Ozempic, Qelbree, REXULTI, REZDIFFRA, RINVOQ, Rybelsus, SKYRIZI, TRELEGY ELLIPTA, TREMFYA, VOQUEZNA, VOWST, VRAYLAR, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error